

# The Executive Office of Health & Human Services

## Pharmacy and Therapeutics Committee Meeting Minutes



Tuesday, April 13, 2021

8:00 AM

Gainwell Technologies

Location: Virtual

**P & T Members Present:** Greg Allen, MD  
 Todd Brothers, PharmD  
 Nickolai Morin, PharmD  
 Matt Salisbury, MD  
 Tracey Taviera, PharmD  
 Rick Wagner, MD

**Absent:** Bill Quirk, RPh

**Others Present:** Ann Bennett, MHA (Gainwell Technologies)  
 Jerry Fingerut, MD, Medical Director, (EOHHS)  
 Dezeree Hodish, Assistant Director Financial and Contract Management (EOHHS)  
 Karen Mariano, RPh (Gainwell Technologies)  
 Kathryn Novak, RPh (Magellan Medicaid Administration)

The meeting was called to order by the Chairperson once a quorum was in attendance - 8:07 am. Chairman Tracey Taviera called the meeting to order and asked for introductions the committee and those supporting the meeting. The December 15<sup>th</sup>, 2020 meeting minutes were reviewed and by vote were accepted as presented. The following topics were discussed: election of Todd Brothers as committee co-chair, by-laws review including expansion of committee and length of public testimony. By-laws review will be scheduled for the June meeting.

**Public testimony included the following speakers and topics.**

Follow up information should be sent to karen.mariano@gainwelltechnologies.com for distribution to the committee.

P & T Speaker	Affiliation	Topic
Wendy Borgersen	Red Hill BioPharm	Talicia
Elizabeth Lubelczyk	Lilly	Trulicity
Niki Patel	NovoNordisk	Rybelsus & Ozempic

Magellan Medicaid Administration (MMA) presented the following categories for therapeutic class reviews with discussion from the pharmacy and therapeutics committee.

Therapeutic Categories		Comments & Discussion	Vote:Yes	Vote:No	Abstain	Motion
<b>Blood Modifying Agents</b>	Antihyperuricemics	ACR updated gout guideline. Recommendation changes to the PDL are to add Colcrys and remove colchicine/Mitigare tablets. Motion to accept the recommendations.	All			Pass
	Bile Salts	No new relevant clinical information. Allergan no longer making Actigall. Recommend no change to the PDL. Motion to accept the recommendations.	All			Pass
	Erythropoiesis Stimulating Proteins	No new relevant clinical information. Recommend no change to the PDL. Motion to accept the recommendations.	All			Pass
	Phosphate Binders	No new relevant clinical information. Recommended changes to the PDL are to add Renvela and to remove sevelamer. Motion to accept the recommendations.	All			Pass
	Potassium Binders	No new relevant clinical information. Recommend no change to the PDL. Motion to accept the recommendations.	All			Pass

Therapeutic Categories (cont.)		Comments & Discussion	Vote:Yes	Vote:No	Abstain	Motion	
Endocrine Agents	Androgenic Agents	No new relevant clinical information. Recommend no change to the PDL. Motion to accept the recommendations.	All			Pass	
	Bone Resorption Inhibitors	Joint statement for management of osteoporosis released. Recommend no change to the PDL. Motion to accept the recommendations.	All			Pass	
	Glucagon Agents	No new agents in the category. Recommend no change to the PDL. Motion to accept the recommendations.	All			Pass	
	Growth Hormones	No new clinical information in this class. Compliance at 82%; due to wrap around benefit. Recommend no change to the PDL. Motion to accept the recommendations. Discussion: in other States is there step therapy/work up for growth hormone? Yes. Similar for RI. Any denial of PA based on clinical info? No.	All			Pass	
	Hypoglycemics		New information from ACC, ADA and KDIGO relevant to diabetics/comorbidities. Question: because of new algorithms is there new step therapy in other States? Generally, cornerstone is metformin; most agents are add on therapy.				
		alpha-glucosidase inhibitors	No new relevant clinical information. Recommend no change to the PDL. Motion to accept the recommendations.	All			Pass
		incretin mimetics/enhancers	FDA communication: Januvia & Janumet are not proved to improve glycemic control in youth. Recommend addition of Trulicity. Noting discontinuation of Bydureon (weekly) pens. Leaves Victoza for daily and Trulicity as weekly. Motion to accept the recommendations.	All			Pass
		insulins	Two new biologics SEMGLEE (insulin glargline) and LYUMJEV (insulin lispro-aabc). Changes to add insulin aspart cartridges, pens and vials, insulin aspart/insulin aspart protamine pens and vials, insulin lispro junior kwikpen, insulin lispro protamine mix kwikpen, insulin lispro pen and vials, and Humulin 500 U/M pen. Motion to accept the recommendations.	All			Pass
		meglitinides	No new relevant clinical information. Recommend no change to the PDL. Motion to accept the recommendations.	All			
		metformins	No new relevant clinical information. Recommend no change to the PDL. Motion to accept the recommendations. Discussion: Confirm patients will be grandfathered? Yes; based on current utilization/within recent 90 days.	All			Pass
		SGLT2s	FDA drug safety communication updated the BBW. Re: leg & foot amputations based on 3 new clinical trials have removed warning on the canagliflozin containing medications; removed BBW. Recommend addition of Synjardy. Discussion: Do other states have new step therapy as a result of the new recommendations? Yes. Refer to DUR committee. Question: does recommendation include Synjardy XR? Would like to consider adding this; compliance increased with less daily doses. Recommendation does not include XR. Currently federal legislation related to UROA for XR making the drug not cost effective. Product is available via PA. Motion to accept the recommendations.	All			Pass
		sulfonylureas	No new relevant clinical information. Recommend no change to the PDL. Motion to accept the recommendations.	All			Pass
thiazolidinediones	No new relevant clinical information. Recommend no change to the PDL. Motion to accept the recommendations.	All			Pass		

Therapeutic Categories (cont.)		Comments & Discussion	Vote:Yes	Vote:No	Abstain	Motion
<b>GI Agents</b>	Pancreatic Enzymes	No new relevant clinical information. Recommend no change to the PDL. Motion to accept the recommendations.	All			Pass
	Progestins for Cachexia	No new relevant clinical information. Recommend no change to the PDL. Motion to accept the recommendations.	All			Pass
	Antiemetics	New product information Gimoti (metoclopramide) 15mg/nasal spray with acute and recurrent diabetic gastroparesis. Recommend no change to the PDL. Motion to accept the recommendations.	All			Pass
	GI Motility, Chronic	No new relevant clinical information. Recommend no change to the PDL. Motion to accept the recommendations.	All			Pass
	H. Pylori Agents	New product Talicia. Recommend no change to the PDL. Discussion; no FDA approval of superiority for Talecia. Motion to accept the recommendations.	All			Pass
	Proton Pump Inhibitors	Update to AGA and JTF to management of EoE. SARS CoV 2 updates PP dose related increased odds ratio. No change to PDL. Discussion: originally discussion regarding dose limits. Given SARS 2 info are any states limiting? Add to DUR. Motion to accept the recommendations.	All			Pass
	Ulcerative Colitis	No new relevant clinical information. Recommendations are to add Apriso, Canasa, Rowasa; and non-prefer generics for Canasa/SF Rowasa. Motion to accept the recommendations.	All			Pass

## 2021 Schedule

June 8th

September 21st

December 14th

## Adjournment

The meeting adjourned at 9:37 AM